$2.72
+0.01 (+0.37%)
Open$2.80
Previous Close$2.71
Day High$2.92
Day Low$2.64
52W High$41.22
52W Low$2.52
Volume—
Avg Volume386.8K
Market Cap9.59M
P/E Ratio—
EPS$-10.20
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+809.6% upside
Current
$2.72
$2.72
Target
$24.74
$24.74
$16.96
$24.74 avg
$28.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.58M | 4.80M | 3.77M |
| Net Income | 640.0K | 637.0K | 538.3K |
| Profit Margin | 14.0% | 13.3% | 14.3% |
| EBITDA | 1.20M | 1.08M | 968.7K |
| Free Cash Flow | 434.6K | 468.2K | 383.2K |
| Rev Growth | +11.7% | 0.0% | +15.1% |
| Debt/Equity | 0.17 | 0.18 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |